Large cap U.S. listed equity portfolio that offers above-average dividend income and defensive characteristics.
In an investment landscape that features scarcity of income yield in U.S. public equities, U.S. Equity Income aims to generate sustainable and above-average dividend income streams via investments in high quality U.S. listed companies.
The portfolio is composed of large-cap defensive equities with a heavy tilt towards defensive sectors such as Healthcare, Consumer Staples, Utilities and Communication Services. As such, U.S. Equity Income features lower sensitivity (low beta) to the broad U.S. equity indices and its low volatility profile enables strong downside protection.
Portfolio construction is based on quantitative scoring of our U.S. equity universe with a focus on Value, Quality, Safety, Payout, Technical and Sentiment metrics, as well as ESG traits. In particular, the Quality and Safety metrics ensure that stock selection is geared towards low-risk companies that exhibit high levels of profitability and low financial leverage.
|Asset Class||Weight (%)|
|1. Bristol-Myers Squibb Co||4.38%|
|2. Swisscom AG||4.37%|
|3. Medtronic PLC||4.37%|
|4. Crown Castle Inc||4.37%|
|5. Novartis AG||4.36%|
|6. Kimberly-Clark Corp||4.35%|
|7. Vodafone Group PLC||4.35%|
|8. Takeda Pharmaceutical Co Ltd||4.34%|
|9. Exxon Mobil Corp||4.34%|
|10. International Business Machines Corp||4.34%|